TABLE 2.

Parameter Estimate of the Joint Model

Variable	Coefficient	95% CI	P
Longitudinal submodela
Intercept	0.39	0.29 to 0.48
Treatment (CT + B v CT)	0.01	–0.11 to 0.14	.862
Baseline lNLR (≥1.10 v <1.10)	0.52	0.38 to 0.65	<.001
Treatment × baseline lNLR	–0.26	–0.47 to –0.06	.012

Variable	Coefficient	95% CI	P	HR	95% CI
Survival submodel
Treatment (CT + B v CT) in baseline lNLR <1.10 group	–0.41	–0.79 to –0.03	.037	0.66	0.45 to 0.98
Baseline lNLR (≥1.10 v <1.10) in CT + B group	0.56	0.10 to 1.02	.017	1.75	1.10 to 2.77
Treatment × baseline lNLR	0.90	0.30 to 1.50	.003
Assoc	1.39	0.95 to 1.82	<.001	4.00	2.60 to 6.17

Abbreviations: B, bevacizumab; CT, chemotherapy; CT + B, chemotherapy + bevacizumab; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio.

^a The regression coefficients for the natural cubic splines were omitted as not directly interpretable.